7890
S. M. Allin et al. / Tetrahedron Letters 42 (2001) 7887–7890
CHO
H
CHO
3b
H
N
MeO2C
MeO2C
MeO2C
•
•
N
N
O
O
N
N
H
N
H
N
N
CO2Me
CO2Me
CO2Me
4b
22 AIBMe
24
23
3b
4b
Scheme 7. Role of ‘initiator’ in the oxidative step of the oxidative cyclisation. Bu3SnH (1.5 equiv.) and AIBMe (2.0 equiv.) were
added by syringe pump to a solution of 1b under reflux and an atmosphere of CO over 5 h and refluxed for further 3 h.
clear cut. The mechanism of rearomatisation is still
unclear and is discussed in Ref. 11. In the Bu3SnH
mediated oxidative cyclisations reported in the litera-
ture, greater than one equivalent of AIBN is required
suggesting that AIBN is involved with a H-abstraction
mechanism for this step. Azo compounds are known to
act as oxidants and therefore dihydro-AIBN would be
expected as a product, but is unstable to the reaction
conditions and cannot be isolated. Therefore, in initial
studies, AIBMe 22 [azobisisobutyrate methyl ester, or
by IUPAC nomenclature, 2-(1-methoxycarbonyl-1-
methyl-ethylazo)-2-methyl-propionic acid methyl ester]
was used (Scheme 7). Cyclisation of 1b gave the cyclised
product 4b (30%) and dihydro-AIBMe 23 (17%) (analy-
Soc., Perkin Trans. 1 2000, 1; (b) Aldabbagh, F.; Bow-
man, W. R. Contemporary Org. Synth. 1997, 4, 261.
2. (a) Aldabbagh, F.; Bowman, W. R.; Mann, E. Tetra-
hedron Lett. 1997, 38, 7937–7940; (b) Aldabbagh, F.;
Bowman, W. R.; Mann, E.; Slawin, A. M. Z. Tetrahedron
1999, 55, 8111.
3. Antonio, Y.; De La Cruz, E.; Galeazzi, E.; Guzman, A.;
Bray, B. L.; Greenhouse, R.; Kurz, L. J.; Lustig, D. A.;
Maddox, M. L.; Muchowski, J. M. Can. J. Chem. 1994,
72, 15–22.
4. Ziegler, F. E.; Belema, M. J. Org. Chem. 1997, 62,
1083–1094.
5. Moody, C. J.; Norton, C. L. J. Chem. Soc., Perkin Trans.
1 1997, 2639–2643.
1
sis by H NMR spectroscopy using an internal stan-
6. (a) Tim, C. T.; Jones, K.; Wilkinson, J. Tetrahedron Lett.
1995, 36, 6743–6744; (b) Dobbs, P. A.; Jones, K.; Veal,
K. T. Tetrahedron 1997, 53, 8287–8289.
7. Suzuki, F.; Kuroda, K. J. Heterocyclic Chem. 1993, 30,
811–813.
dard) indicating that AIBMe is responsible for the
oxidative step. The relative yields indicate the interme-
diate radical 24 oxidises a second equivalent of the
p-radical intermediate 3b to 4b. Alternatively, 24 is
reduced by Bu3SnH to complete a chain reaction by
8. Murphy, J. A.; Sherburn, M. S. Tetrahedron 1991, 47,
4077–4088.
generating Bu3Sn radicals.
9. Harrowen, D.; Nunn, M. I. T. Tetrahedron Lett. 1998,
39, 5875–5876.
10. Marco-Contelles, J.; Rodr´ıquez-Ferna´ndez, M. Tetra-
hedron Lett. 2000, 41, 381–384.
11. Bowman, W. R.; Mann, E.; Parr, J. J. Chem. Soc., Perkin
Trans. 1 2000, 2991–2999.
The products and yields (e.g. cyclisation of 13b to 14b
and 15) differ depending on the conditions used, e.g.
the use of syringe pump addition or sealed tubes, rate
of Bu3SnH addition, presence or absence of CO and the
amount of radical initiator (or oxidant). Further study
is underway to optimise reaction conditions, determine
the mechanism and to develop the protocol for natural
product synthesis.
12. Chatgilialoglu, C.; Crich, D.; Komatsu, M.; Ryu, I.
Chem. Rev. 1999, 99, 1991–2067.
13. Miranda, L. D.; Cruz-Almanza, R.; Paco´n, M.; Alva, E.;
Muchowski, J. M. Tetrahedron Lett. 2000, 40, 7153–7157.
14. (a) Pattenden, G.; Roberts, L.; Blake, A. J. J. Chem.
Soc., Perkin Trans. 1 1998, 863–868; (b) Double, P.;
Pattenden, G. J. Chem. Soc., Perkin Trans. 1 1998,
2005–2007 and references cited therein.
Acknowledgements
15. Nicolaou, K. C.; Petasis, N. A.; Claremon, D. A. Tetra-
hedron 1985, 41, 4835–4841.
16. Bray, B. L.; Mathies, P. H.; Naef, R.; Solas, D. R.;
Tidwell, T. T; Artis, D. R.; Muchowski, J. M. J. Org.
Chem. 1990, 55, 6317–6328.
17. Hartmann, T.; Witte, L. In Alkaloids: Chemical and Bio-
logical Persepectives; Pelletier, S. W., Ed.; Pergamon
Press: Oxford, 1996; Vol. 9, pp. 155–233. Recent synthe-
sis: Miranda, L. D.; Cruz-Almanza, R.; Alvarez-Garcia´,
A; Muchowski, J. M. Tetrahedron Lett. 2000, 40, 3035–
3038.
We thank AstraZeneca (R&D Charnwood) and the
EPSRC for an EPSRC CASE Postgraduate Research
Studentship (WRSB), AstraZeneca (R&D Charnwood)
for generous funding and the EPSRC Mass Spectrome-
try Unit, Swansea University, Wales for mass spectra.
References
1. (a) Bowman, W. R.; Bridge, C. F.; Brookes, P. J. Chem.